Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Ox40 CRISPR/Cas9 KO Plasmid (h): sc-401326
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Ox40 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Ox40 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Ox40 Antibody (H-10): sc-376014
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ox40 CRISPR/Cas9 KO Plasmid (h) | sc-401326 | 20 µg | $397.00 |
Overview
TNFRSF4 encodes OX40 (CD134), an inducible costimulatory receptor of the TNF receptor superfamily expressed primarily on activated CD4+ and CD8+ T cells and subsets of regulatory T cells. Upon engagement by OX40L (TNFSF4), OX40 promotes T-cell expansion, survival, and memory formation through recruitment of TRAF adaptors and downstream activation of NF-κB, MAPK, and PI3K/AKT signaling. This axis modulates cytokine production, germinal center support, and the balance between effector and regulatory responses. Dysregulated OX40 signaling has been implicated in chronic inflammation and autoimmune disease mechanisms, and it is also relevant to immune evasion and tumor-associated T-cell dysfunction in cancer biology.
Ox40 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TNFRSF4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TNFRSF4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TNFRSF4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Ox40 protein expression.
This CRISPR knockout system enables efficient generation of TNFRSF4-deficient cell models for investigation of Ox40 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TNFRSF4 exon(s) critical for Ox40 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TNFRSF4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Ox40 CRISPR/Cas9 KO Plasmid (h) and Ox40 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TNFRSF4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Ox40 HDR Plasmid (h) and Ox40 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TNFRSF4 homology arms to support homology-directed repair at defined TNFRSF4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.